Details of the Drug

General Information of Drug (ID: DMIUW25)

Drug Name
Granisetron
Synonyms
BRL-43694; Kytril (TN); Granisetron (USAN/INN); 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide; 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
Indication
Disease Entry ICD 11 Status REF
Nausea and vomiting MD90 Approved [1]
Therapeutic Class
Antiemetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 312.4
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 60% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.1 mL/min/kg [4]
Elimination
11% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 6 hours [4]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03201 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.35% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.7 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [2]
Chemical Identifiers
Formula
C18H24N4O
IUPAC Name
1-methyl-N-[(1R,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
Canonical SMILES
CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
InChI
InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+
InChIKey
MFWNKCLOYSRHCJ-AGUYFDCRSA-N
Cross-matching ID
PubChem CID
5284566
ChEBI ID
CHEBI:5537
CAS Number
109889-09-0
DrugBank ID
DB00889
TTD ID
D0J5KF
VARIDT ID
DR00439
INTEDE ID
DR0788
ACDINA ID
D00614

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3 receptor (5HT3R) TTNXLKE NOUNIPROTAC Antagonist [6], [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [8]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Granisetron
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Granisetron and Promethazine. Nausea/vomiting [MD90] [66]
Coadministration of a Drug Treating the Disease Different from Granisetron (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Granisetron and Methylene blue. Acquired methaemoglobinaemia [3A93] [66]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Granisetron and Ivosidenib. Acute myeloid leukaemia [2A60] [67]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Granisetron and Idarubicin. Acute myeloid leukaemia [2A60] [66]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Granisetron and Arn-509. Acute myeloid leukaemia [2A60] [68]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Granisetron and Gilteritinib. Acute myeloid leukaemia [2A60] [69]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Granisetron and Oliceridine. Acute pain [MG31] [66]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Rivastigmine. Alzheimer disease [8A20] [66]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Granisetron and Metronidazole. Amoebiasis [1A36] [70]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Granisetron and Ivabradine. Angina pectoris [BA40] [68]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Granisetron and Bepridil. Angina pectoris [BA40] [66]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Granisetron and Dronedarone. Angina pectoris [BA40] [66]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Granisetron and Cilostazol. Arterial occlusive disease [BD40] [66]
Posaconazole DMUL5EW Moderate Decreased metabolism of Granisetron caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [68]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Levalbuterol. Asthma [CA23] [71]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Pirbuterol. Asthma [CA23] [72]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Salbutamol. Asthma [CA23] [71]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Formoterol. Asthma [CA23] [72]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [68]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Granisetron and Desipramine. Attention deficit hyperactivity disorder [6A05] [66]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Ofloxacin. Bacterial infection [1A00-1C4Z] [73]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Granisetron caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [74]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Granisetron and Clarithromycin. Bacterial infection [1A00-1C4Z] [66]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Granisetron and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [66]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Granisetron and Sparfloxacin. Bacterial infection [1A00-1C4Z] [73]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Granisetron and Gemifloxacin. Bacterial infection [1A00-1C4Z] [73]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Norfloxacin. Bacterial infection [1A00-1C4Z] [73]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Granisetron and Levofloxacin. Bacterial infection [1A00-1C4Z] [73]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Granisetron and Lomefloxacin. Bacterial infection [1A00-1C4Z] [66]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Granisetron caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [75]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Granisetron and Retigabine. Behcet disease [4A62] [66]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Granisetron and Eribulin. Breast cancer [2C60-2C6Y] [66]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Granisetron caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [76]
Tucatinib DMBESUA Moderate Decreased metabolism of Granisetron caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [77]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Granisetron and Bosutinib. Breast cancer [2C60-2C6Y] [68]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Granisetron and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [78]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Olodaterol. Chronic obstructive pulmonary disease [CA22] [72]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Vilanterol. Chronic obstructive pulmonary disease [CA22] [71]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Salmeterol. Chronic obstructive pulmonary disease [CA22] [72]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Arformoterol. Chronic obstructive pulmonary disease [CA22] [72]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Granisetron and Dihydrocodeine. Chronic pain [MG30] [79]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Granisetron and Levomilnacipran. Chronic pain [MG30] [66]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Granisetron and Isoproterenol. Conduction disorder [BC63] [71]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Sevoflurane. Corneal disease [9A76-9A78] [66]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Granisetron and Remifentanil. Corneal disease [9A76-9A78] [66]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Granisetron and Probucol. Coronary atherosclerosis [BA80] [66]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Granisetron and Pasireotide. Cushing syndrome [5A70] [66]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Granisetron and Osilodrostat. Cushing syndrome [5A70] [68]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Granisetron caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [80]
MK-8228 DMOB58Q Moderate Decreased metabolism of Granisetron caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [81]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Granisetron and Sertraline. Depression [6A70-6A7Z] [66]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Granisetron and Vilazodone. Depression [6A70-6A7Z] [66]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Granisetron and Nefazodone. Depression [6A70-6A7Z] [66]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Granisetron and Vortioxetine. Depression [6A70-6A7Z] [66]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Granisetron and Isocarboxazid. Depression [6A70-6A7Z] [66]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Granisetron and Milnacipran. Depression [6A70-6A7Z] [66]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Granisetron and Escitalopram. Depression [6A70-6A7Z] [66]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Granisetron and Desvenlafaxine. Depression [6A70-6A7Z] [66]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Granisetron and Doxepin. Depression [6A70-6A7Z] [70]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Granisetron and Maprotiline. Depression [6A70-6A7Z] [66]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Granisetron and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [70]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Granisetron and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [66]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Granisetron and Deutetrabenazine. Dystonic disorder [8A02] [82]
Cenobamate DMGOVHA Moderate Increased metabolism of Granisetron caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Stiripentol DMMSDOY Moderate Decreased metabolism of Granisetron caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [84]
Rufinamide DMWE60C Moderate Increased metabolism of Granisetron caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [68]
Phenobarbital DMXZOCG Minor Increased metabolism of Granisetron caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [85]
Tazemetostat DMWP1BH Moderate Increased metabolism of Granisetron caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [86]
Ketoconazole DMPZI3Q Minor Decreased metabolism of Granisetron caused by Ketoconazole. Fungal infection [1F29-1F2F] [85]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Granisetron and Sunitinib. Gastrointestinal stromal tumour [2B5B] [66]
Boceprevir DMBSHMF Moderate Decreased metabolism of Granisetron caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [87]
Telaprevir DMMRV29 Moderate Decreased metabolism of Granisetron caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [88]
Rifapentine DMCHV4I Moderate Increased metabolism of Granisetron caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [89]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Granisetron and Procarbazine. Hodgkin lymphoma [2B30] [66]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Granisetron caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [90]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Granisetron and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [91]
Etravirine DMGV8QU Moderate Increased metabolism of Granisetron caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [92]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Granisetron and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [66]
Darunavir DMN3GCH Moderate Decreased metabolism of Granisetron caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [93]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Granisetron caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [94]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Polyethylene glycol. Irritable bowel syndrome [DD91] [68]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Phenolphthalein. Irritable bowel syndrome [DD91] [66]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Granisetron and Crizotinib. Lung cancer [2C25] [95]
Brigatinib DM7W94S Moderate Increased metabolism of Granisetron caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [96]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Granisetron and Ceritinib. Lung cancer [2C25] [66]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Granisetron and Osimertinib. Lung cancer [2C25] [97]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Granisetron and Lumefantrine. Malaria [1F40-1F45] [70]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Granisetron and Halofantrine. Malaria [1F40-1F45] [98]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Granisetron and Hydroxychloroquine. Malaria [1F40-1F45] [99]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Granisetron and Primaquine. Malaria [1F40-1F45] [66]
Idelalisib DM602WT Moderate Decreased metabolism of Granisetron caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [100]
IPI-145 DMWA24P Moderate Decreased metabolism of Granisetron caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [101]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Granisetron and Arsenic trioxide. Mature B-cell lymphoma [2A85] [102]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Granisetron and Vemurafenib. Melanoma [2C30] [66]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Granisetron and LGX818. Melanoma [2C30] [103]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Granisetron caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [68]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Granisetron and Almogran. Migraine [8A80] [66]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Granisetron and Frovatriptan. Migraine [8A80] [66]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Granisetron and Rizatriptan. Migraine [8A80] [66]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Granisetron and Naratriptan. Migraine [8A80] [66]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Granisetron and Lasmiditan. Migraine [8A80] [66]
Exjade DMHPRWG Moderate Decreased metabolism of Granisetron caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [104]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Granisetron and Thalidomide. Multiple myeloma [2A83] [70]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Granisetron and Fingolimod. Multiple sclerosis [8A40] [66]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Granisetron and Ozanimod. Multiple sclerosis [8A40] [105]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Granisetron and Romidepsin. Mycosis fungoides [2B01] [66]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Granisetron caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [68]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Granisetron and Nilotinib. Myeloproliferative neoplasm [2A20] [66]
Dasatinib DMJV2EK Moderate Decreased metabolism of Granisetron caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [106]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Granisetron and Entrectinib. Non-small cell lung cancer [2C25] [70]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Granisetron and Sibutramine. Obesity [5B80-5B81] [66]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Granisetron and Dexfenfluramine. Obesity [5B80-5B81] [66]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Granisetron and Levomethadyl Acetate. Opioid use disorder [6C43] [68]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Granisetron and Lofexidine. Opioid use disorder [6C43] [66]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Rucaparib. Ovarian cancer [2C73] [66]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Granisetron and Dezocine. Pain [MG30-MG3Z] [79]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Granisetron and Buprenorphine. Pain [MG30-MG3Z] [66]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Granisetron and Hydrocodone. Pain [MG30-MG3Z] [79]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Granisetron and Triclabendazole. Parasitic worm infestation [1F90] [66]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Granisetron and Pimavanserin. Parkinsonism [8A00] [107]
Abametapir DM2RX0I Moderate Decreased metabolism of Granisetron caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [108]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Granisetron and Famotidine. Peptic ulcer [DA61] [70]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Granisetron and Macimorelin. Pituitary gland disorder [5A60-5A61] [109]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Granisetron and Lefamulin. Pneumonia [CA40] [110]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Granisetron caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [111]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Granisetron and Degarelix. Prostate cancer [2C82] [68]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Granisetron and ABIRATERONE. Prostate cancer [2C82] [68]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Granisetron and Enzalutamide. Prostate cancer [2C82] [68]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Granisetron and Relugolix. Prostate cancer [2C82] [68]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Granisetron and Bicalutamide. Prostate cancer [2C82] [68]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Granisetron and Levomepromazine. Psychotic disorder [6A20-6A25] [66]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Granisetron and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [112]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Granisetron and Gatifloxacin. Respiratory infection [CA07-CA4Z] [113]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Granisetron and Quetiapine. Schizophrenia [6A20] [66]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Granisetron and Mesoridazine. Schizophrenia [6A20] [66]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Granisetron and Aripiprazole. Schizophrenia [6A20] [70]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Granisetron and Iloperidone. Schizophrenia [6A20] [66]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Granisetron and Amisulpride. Schizophrenia [6A20] [114]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Asenapine. Schizophrenia [6A20] [66]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Granisetron and Pimozide. Schizophrenia [6A20] [68]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Granisetron caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [68]
Larotrectinib DM26CQR Moderate Decreased metabolism of Granisetron caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [70]
Armodafinil DMGB035 Minor Increased metabolism of Granisetron caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [115]
LEE011 DMMX75K Major Decreased metabolism of Granisetron caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [66]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Granisetron and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [66]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Granisetron and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [68]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Granisetron and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [66]
Pitolisant DM8RFNJ Moderate Increased metabolism of Granisetron caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [68]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Granisetron and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [66]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Granisetron caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [116]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Granisetron and Lenvatinib. Thyroid cancer [2D10] [66]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Granisetron and Cabozantinib. Thyroid cancer [2D10] [68]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Granisetron and Papaverine. Tonus and reflex abnormality [MB47] [117]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Granisetron and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [118]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Granisetron and Procainamide. Ventricular tachyarrhythmia [BC71] [66]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Granisetron and Propafenone. Ventricular tachyarrhythmia [BC71] [66]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Granisetron and Flecainide. Ventricular tachyarrhythmia [BC71] [66]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Granisetron and Amiodarone. Ventricular tachyarrhythmia [BC71] [66]
⏷ Show the Full List of 157 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Granisetron 1 mg tablet 1 mg Oral Tablet Oral
Granisetron Hydrochloride eq 1mg base/ml injectable eq 1mg base/ml Injectable Injection
Granisetron Hydrochloride eq 1mg base tablet eq 1mg base Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
7 Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1993 Apr;7(2):175-80.
8 CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
9 Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.
10 Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos. 1999 Jan;27(1):110-2.
11 Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994 Dec;38(6):557-66.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
23 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
24 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
25 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
26 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
27 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
29 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
30 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
31 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
32 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
33 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
34 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
35 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
36 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
37 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
38 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
39 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
40 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
41 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
42 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
43 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
44 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
45 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
46 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
47 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
48 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
49 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
50 Drug Interactions Flockhart Table
51 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
52 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
53 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
54 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
55 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
56 Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
57 Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
58 The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
59 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
60 Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
61 Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
62 Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
63 Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
64 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
65 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
66 Canadian Pharmacists Association.
67 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
68 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
69 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
70 Cerner Multum, Inc. "Australian Product Information.".
71 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
72 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
73 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
74 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
75 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
76 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
77 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
78 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
79 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
80 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
81 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
82 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
83 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
84 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
85 Product Information. Kytril (granisetron). SmithKline Beecham, Philadelphia, PA.
86 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
87 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
88 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
89 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
90 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
91 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
92 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
93 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
94 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
95 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
96 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
97 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
98 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
99 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
100 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
101 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
102 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
103 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
104 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
105 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
106 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
107 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
108 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
109 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
110 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
111 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
112 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
113 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
114 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
115 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
116 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
117 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
118 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]